Brief: Elevation Oncology Inc Seribantumab Included As Part Of A Case Series Presentation At The Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting
14/10/2021 12:26
Oct 14 (Reuters) - Elevation Oncology Inc ELEV.O :
* ELEVATION ONCOLOGY'S SERIBANTUMAB INCLUDED AS PART OF A
CASE
SERIES PRESENTATION AT THE AUSTRALASIAN GASTRO-INTESTINAL TRIALS
GROUP 2021 ANNUAL SCIENTIFIC MEETING
Source text for Eikon: ID:nPn28x3mTa
Further company coverage: ELEV.O
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing